Pyrolyx AG News - PLX

FeaturedECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch

Fidelity Management & Research Co. 3Q 13F: Largest Eliminations

DJ CFA SOURCE: SEC 13F-HR FILER: Fidelity Management & Research Co. QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 Up to 200 of the...

Fidelity Management & Research Co. 3Q 13F: Largest Purchases

DJ CFA SOURCE: SEC 13F-HR FILER: Fidelity Management & Research Co. QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 Up to 200 of the...

Protalix BioTherapeutics Discloses Three New Compounds in Development

- Oral PRX-106 for immune mediated disorders - PRX-110 for Cystic Fibrosis (CF) - PRX-107 for emphysema due to hereditary alpha1-antitrypsin...

Protalix BioTherapeutics and Brazil's Ministry of Health Enter Into Supply and Technology Transfer Agreement for UPLYSO(TM) (al

CARMIEL, Israel, June 19, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that it has entered...

Protalix BioTherapeutics to Host Analyst Event in New York City

CARMIEL, Israel, June 12, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), will be hosting an analyst event on...

Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

CARMIEL, Israel, May 29, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), today announced that senior...

Protalix BioTherapeutics to Present at the Oppenheimer 14th Annual Israeli Conference

CARMIEL, Israel, May 8, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that Dr. David...

UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease

CARMIEL, Israel, April 29, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that the Mexican...

Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of

CARMIEL, Israel, April 2, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first...

UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease

NEW YORK and CARMIEL, Israel, March 18, 2013 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE MKT:PLX...

Protalix BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher Patients With PRX-112, an Orally-Administered C

CARMIEL, Israel, March 7, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that it has received...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Pyrolyx AG (PLX)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

PLX News

FeaturedECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch

Fidelity Management & Research Co. 3Q 13F: Largest Eliminations

Fidelity Management & Research Co. 3Q 13F: Largest Purchases

Protalix BioTherapeutics Discloses Three New Compounds in Development

Protalix BioTherapeutics and Brazil's Ministry of Health Enter Into Supply and Technology Transfer Agreement for UPLYSO(TM) (al

Protalix BioTherapeutics to Host Analyst Event in New York City

Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

Protalix BioTherapeutics to Present at the Oppenheimer 14th Annual Israeli Conference

UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease

Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of

UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease

Protalix BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher Patients With PRX-112, an Orally-Administered C

PLX Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Pyrolyx AG (PLX) News

Pyrolyx AG (PLX)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

PLX News

FeaturedECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch

Fidelity Management & Research Co. 3Q 13F: Largest Eliminations

Fidelity Management & Research Co. 3Q 13F: Largest Purchases

Protalix BioTherapeutics Discloses Three New Compounds in Development

Protalix BioTherapeutics and Brazil's Ministry of Health Enter Into Supply and Technology Transfer Agreement for UPLYSO(TM) (al

Protalix BioTherapeutics to Host Analyst Event in New York City

Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

Protalix BioTherapeutics to Present at the Oppenheimer 14th Annual Israeli Conference

UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease

Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of

UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease

Protalix BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher Patients With PRX-112, an Orally-Administered C

PLX Discussion

Your Recent History